nelfinavir has been researched along with ritonavir in 312 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (17.95) | 18.2507 |
| 2000's | 210 (67.31) | 29.6817 |
| 2010's | 38 (12.18) | 24.3611 |
| 2020's | 8 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Almond, MR; Bock, WJ; Cleary, DG; Furfine, ES; Hazen, RJ; Kazmierski, WM; Salituro, FG; Spaltenstein, A; Tung, RD; Wright, LL | 1 |
| Chen, IW; Darke, PL; Dorsey, BD; Emini, EA; Hoffman, JM; Holloway, MK; Huff, JR; Kuo, LC; Levin, RB; Lin, JH; McDaniel, SL; McDonough, C; Michelson, SR; Newton, CL; Olsen, DB; Rutkowski, CA; Schleif, WA; Stahlhut, MW; Vacca, JP; Zugay-Murphy, JA | 1 |
| Classon, B; Hallberg, A; Kvarnström, I; Lindberg, J; Pyring, D; Samuelsson, B; Unge, T; Vrang, L; Zhang, H; Zuccarello, G | 1 |
| Classon, B; Hallberg, A; Mühlman, A; Samuelsson, B | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Danielson, UH; Hallberg, A; Hämäläinen, M; Karlén, A; Markgren, PO; Samuelsson, B; Schaal, W | 1 |
| Kim, RB; Leake, BF; Tirona, RG; Wolkoff, AW | 1 |
| Freire, E; Muzammil, S; Ross, P | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R | 1 |
| Gupta, A; Mao, Q; Unadkat, JD; Zhang, Y | 1 |
| Agbandje-McKenna, M; Clemente, JC; Dunn, BM; Goodenow, MM; Govindasamy, L; Hemrajani, R; McKenna, R; Moose, RE; Reutzel, R; Whitford, LR | 1 |
| Danielson, UH; Shuman, CF; Vrang, L | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT | 1 |
| Garg, R; Patel, D | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Kimura, T; Kiso, Y; Nakahara, K; Nakatani, S; Nguyen, JT; Sato, A | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Hori, Y; Kimura, T; Kiso, Y; Nagai, A; Nakahara, K; Nakatani, S; Nguyen, JT; Ohnishi, N; Sato, A | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Diederich, WE; Kuhnert, M; Steuber, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL | 1 |
| Deeks, SG; Holodniy, M; Kahn, JO; Smith, M | 1 |
| Fox, JL | 1 |
| Kuritzkes, DR; McDonald, CK | 1 |
| Cao, Y; Ho, DD; Markowitz, M; Saksela, K; Vesanen, M | 1 |
| Ferrando, S; Rabkin, JG | 1 |
| Delwart, EL; Markowitz, M; Neumann, A; Pan, H | 1 |
| Grodesky, MJ; Klaus, BD | 1 |
| Chiba, N; Hayashi, H; Shintani, M; Ueno, T | 1 |
| Burton, S; Carr, A; Chisholm, DJ; Cooper, DA; Freund, J; Law, M; Samaras, K | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Saag, MS; Schooley, RT | 1 |
| Boden, D; Markowitz, M | 1 |
| Blaschke, TF; Duran, GE; Man, MC; Sikic, BI; Washington, CB | 1 |
| Chronister, CL; Gurwood, AS | 1 |
| Lien, EJ; Ren, S | 1 |
| Holtzer, CD; Varav, H | 1 |
| Kuper, JJ; Malaty, LI | 1 |
| Erice, A; Henry, K; Kane, EM; Klebert, MK; Patick, AK; Powderly, WG; Simpson, JH; Tebas, P | 1 |
| Carver, PL; Cinti, SK; Kaul, DR; Kazanjian, PH | 1 |
| Dubreuil, L; Gérard, Y; Maulin, L; Mouton, Y | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP; Wuis, EW | 1 |
| Brendel, V; Craig, C; Hsu, P; Patick, AK; Shafer, RW | 1 |
| Barnett, SH; Gallant, JE; Hall, CS; Moore, RD; Raines, CP | 1 |
| Clough, LA; D'Agata, E; Haas, DW; Raffanti, S | 1 |
| Fitzgibbon, JE; Hua, J; Liao, MJ; Moussazadeh, M; Rashidbaigi, A; Sidhu, MK; Zhao, XX | 1 |
| Cheseaux, JJ; Darioli, R; Glauser, MP; Halfon, P; Marcovina, SM; Mooser, V; Nicod, P; Périard, D; Reymond, MJ; Sudre, P; Telenti, A | 1 |
| Heald, AE; Heffron, S; Schiffman, SS; Zervakis, J | 1 |
| Back, DJ; Eagling, VA; Profit, L | 1 |
| Berger, J; Li, Z; MacNaul, K; Moller, DE; Szalkowski, D; Zhang, B | 1 |
| Abumi, H; Ajisawa, A; Fukutake, K; Gouchi, K; Hanabusa, H; Higasa, S; Ishikawa, M; Iwamoto, A; Kakishita, E; Kashiwagi, S; Koike, M; Matsuda, M; Mimaya, J; Miura, T; Nagai, Y; Oishi, T; Okano, A; Shirahata, A; Sugiura, W; Takamatsu, J; Takata, N; Taki, M; Yamada, K | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Matsumura, Y; Takada, K; Yamaji, H; Yoshikawa, Y | 1 |
| Addo, M; Berthold, HK; Parhofer, KG; Ritter, MM; Rockstroh, JK; Schliefer, K; Spengler, U; Wasmuth, JC | 1 |
| Fletcher, CV; Kawle, SP; Remmel, RP; Weller, D | 1 |
| George, SL; Knudson, R; Stapleton, JT; Swindells, S | 1 |
| Bendfeldt, K; Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R; Wahnschaffe, U; Zippel, T | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
| Blaschke, TF; Giacomini, KM; Gorset, W; Kroetz, DL; Washington, CB; Zhang, L | 1 |
| Danielson, UH; Hämäläinen, M; Markgren, PO | 1 |
| Anderson, C; Craik, CS; Jolly, DJ; Todd, S | 1 |
| Heinrikson, RL; Tomasselli, AG | 1 |
| Klinker, H; Langmann, P; Richter, E; Schlör, C; Väth, T; Weissbrich, B; Zilly, M | 1 |
| Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Zalma, A | 1 |
| Delfraissy, JF; Frau, E; Furlan, V; Goujard, C; Labetoulle, M; Lantz, O; Lecointe, D; Niessen, F; Offret, H; Rogier, H | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Cassol, S; Chambers, KA; Gallicano, K; Hawley-Foss, N; Kravcik, S; Mandy, F; Parato, K; Phenix, BN | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Alessi, F; Bonfanti, P; Carradori, S; Di Cintio, E; Faggion, I; Fortuna, P; Gabbuti, A; Ghiselli, G; Landonio, S; Martinelli, C; Parazzini, F; Pusterla, L; Quirino, T; Timillero, L; Valsecchi, L | 1 |
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Decker, CF; Martin, GJ; Smith, JH | 1 |
| Abeli, C; Adorni, F; Bini, T; Bongiovanni, M; Castelnuovo, B; Chiesa, E; d'Arminio Monforte, A; Melzi, S; Sollima, S; Testa, L | 1 |
| Jaillon, P; Poirier, JM; Radembino, N; Robidou, P | 1 |
| Bryson, YJ; Deville, J; Equils, O; Garratty, E; Krogstad, P; Nielsen, K; Plaeger, S; Sim, MS; Tapia, M; Wei, LS | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Derouin, F; Santillana-Hayat, M | 1 |
| Abrams, E; Aguayo, R; Bamji, M; Dieudonne, A; Jackson, JB; Johnson, G; Kovacs, A; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Rana, S; Sever, J; Stanley, K; Wiznia, A | 1 |
| Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| D'Aquila, RT; Martinez-Picado, J; Savara, AV; Shi, L; Sutton, L | 1 |
| Freire, E; Luque, I; Todd, MJ; Velázquez-Campoy, A | 1 |
| Acosta, E; Cheng, H; Fischl, M; Fiscus, SA; Fletcher, CV; Freimuth, W; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Lagakos, SW; Mills, C; Pettinelli, C; Snyder, S; Swanstrom, R | 1 |
| Gyllensten, K; Sönnerborg, A; Ståhle, L | 1 |
| Tavel, JA | 1 |
| Aebi, C; Cheseaux, JJ; Kind, C; Lazarevitch, CA; Nadal, D; Rudin, C; Steiner, F | 1 |
| Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP | 1 |
| Apuzzo, L; Deetz, C; Eshleman, SH; Fields, C; Flexner, C; Gallant, JE; Heath-Chiozzi, M; Jackson, JB; Lewis, RH; Raines, CP; Sun, E | 1 |
| Croom, DK; Lenhard, JM; Weiel, JE; Winegar, DA | 1 |
| Arimori, K; Fujii, J; Hamada, A; Nakano, M; Shiraki, N; Yasuda, K | 1 |
| Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K | 1 |
| Raffi, F | 1 |
| Greenblatt, DJ; Hesse, LM; Shader, RI; von Moltke, LL | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Bode, H; Fromm, M; Riecken, EO; Schmidt, W; Schulzke, JD; Ullrich, R | 1 |
| Bouley, M; Briere, C; Padoin, C; Petitjean, O; Tod, M | 1 |
| Gatell, J; Lazzarin, A; Lundgren, JD; Miller, V; Mocroft, A; Parkin, JM; Phillips, AN; Roge, B; van Lunzen, J; Weber, R | 1 |
| Koranyi, KI; Nahata, MC; Temple, ME | 1 |
| Kravcik, S | 1 |
| Freire, E; Todd, MJ; Vega, S; Velazquez-Campoy, A | 1 |
| Smart, T | 1 |
| Mascolini, M | 1 |
| Heidere, C | 1 |
| Back, DJ; Davey, R; Hoggard, PG; Jones, K; Khoo, S; Sales, SD | 1 |
| Cunningham, S; Eshleman, SH; Jackson, JB; Johnson, G; Krogstad, P; Lee, S; Nachman, S; Palumbo, P; Wang, YG; Wantman, M; Wei, LJ; Wiznia, A | 1 |
| Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H | 1 |
| Colebunders, R; de Mey, I; Dedes, N; Dreezen, C; Finazzi, R; Florence, E; Koitz, G; Molenberghs, G; Schrooten, W; Youle, M | 1 |
| Funk, MB; Klingebiel, T; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Danielson, UH; Gertow, K; Hämäläinen, M; Karlsson, R; Lindgren, MT; Markgren, PO | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Mitchell, SM; Newson, RB; Zambarakji, HJ | 1 |
| Beall, GN; Chang, ES; Liu, YT; Tetreault, DD | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Cauda, R; Leone, G; Lucia, MB; Rutella, S; Vella, S | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Badley, AD; Lum, JJ; Nie, Z; Phenix, BN; Sanchez-Dardon, J | 1 |
| Back, DJ; Bray, PG; Davey, RA; Jones, K; Khoo, SH; Meaden, ER; Ward, SA | 1 |
| Burger, DM; Chesney, MA; Danner, SA; de Wolf, F; Hoetelmans, RM; Hugen, PW; Jambroes, M; Kauffmann, RH; Lange, JM; Meenhorst, PL; Nieuwkerk, PT; Schneider, MM; Schrey, G; Sprangers, MA; Sprenger, HG; van Der Ende, ME | 1 |
| Gantke, B; Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Borleffs, JC; Boucher, CA; Reedijk, M; Richter, C; Wensing, AM | 1 |
| Pereira, A; Taylor, S | 1 |
| Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
| Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H | 1 |
| Aguayo, R; Dieudonne, A; Jackson, JB; Johnson, G; Khoury, M; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Stanley, K; Wiznia, A | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 2 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A | 1 |
| Jain, RG; Lenhard, JM | 1 |
| Piliero, PJ | 1 |
| Goodsell, DS; Morris, GM; Olson, AJ; Sanner, MF; Stoffler, D | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Choo, PW; Colson, AE; Keller, MJ; Pettus, PT; Platt, R; Sax, PE | 1 |
| Hammer, SM | 1 |
| Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S | 1 |
| Freire, E; Vega, S; Velazquez-Campoy, A | 1 |
| Kaeser, B; Kurowski, M; Mrozikiewicz, A; Popescu, M; Sawyer, A | 1 |
| Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA | 1 |
| Aulagner, G; Bleyzac, N; Bourhis, Y; Coudray, S; Favetta, P; Gagneu, MC; Janoly, A; Oger, I | 1 |
| Rathbun, RC; Rossi, DR; Slater, LN | 1 |
| Carr, A; Chisholm, DJ; Cooper, DA; Gan, SK; Kraegen, EW; Samaras, K; Thompson, CH | 1 |
| Blaschke, TF; Flexner, C; Lu, JF; Rosenkranz, SL; Sheiner, LB | 1 |
| Justesen, US; Pedersen, C | 1 |
| Brodt, HR; Findhammer, S; Helm, EB; Nolte, B; Wolf, T | 1 |
| Aarnoutse, RE; Burger, DM; Droste, JA; Hekster, YA; Koopmans, PP; Popescu, M; Reiss, P; van Oosterhout, JJ | 1 |
| Arcidiacono, MV; Cozzolino, M; Dusso, AS; Tebas, P; Vidal, M; Yarasheski, KE | 1 |
| Antoniou, T; Park-Wyllie, LY | 1 |
| Bratt, G; Ståhle, L | 1 |
| Bergshoeff, AS; Burger, DM; Geelen, SP; Wolfs, TF | 1 |
| Aberg, JA; Blaschke, TF; Flexner, C; Rosenkranz, SL; Segal, Y; Sheiner, LB; Washington, CB | 1 |
| DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G | 1 |
| Burger, DM; Droste, JA; Verweij-Van Wissen, CP | 1 |
| Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D | 1 |
| Hruz, PW; Koster, JC; Nichols, CG; Qiu, H; Remedi, MS | 1 |
| Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
| Fakruddin, JM; Laurence, J | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Brady, M; Cox, S; Crim, L; Gerber, N; Koranyi, K; Utkin, I; Walson, PD | 2 |
| Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C | 1 |
| Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad | 1 |
| Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D | 1 |
| Amari, S; Cinatl, J; Doerr, HW; Fujii, N; Hunsmann, G; Nakano, T; Otaka, A; Rabenau, H; Tamamura, H; Yamamoto, N; Yang, R; Yoshinaka, Y | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Drews, G; Düfer, M; Krippeit-Drews, P; Neye, Y | 2 |
| Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL | 1 |
| DeSilva, KE; Guest, JL; Rimland, D; Ruffin, C; Tschampa, JM | 1 |
| Bellos, NC; DeJesus, E; Garris, C; Gathe, JC; Gladysz, A; Ive, P; Schürmann, D; Wood, R; Yeo, J | 1 |
| Badley, AD; Rouse, MS; Steckelberg, JM; Weaver, JG | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Burger, DM; Colbers, EP; de Graaff-Teulen, MJ; Hekster, YA; Ibanez, SM; Koopmans, PP; la Porte, CJ; Voncken, DS | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Klein, HH; Meier, M; Schütt, M; Zhou, J | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Back, DJ; Janneh, O; Jones, SP; Pirmohamed, M | 1 |
| Brun, SC; Kempf, DJ; King, MS | 1 |
| Badley, AD; Bennett, SA; Bren, GD; Brenner, C; Deniaud, A; Dong, L; Douen, A; Hardin, H; Hou, ST; Jiang, SX; Kroemer, G; Kroemer, RT; Lallier, J; Lebras, M; Lynch, DH; Moffat, TC; Morin, MY; Phenix, BN; Sim, VL; Tarze, A; van Heeswijk, RP; Weaver, JG; Wettstein, P; Zurakowski, B | 1 |
| Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q | 1 |
| Badley, A; Castedo, M; Kroemer, G; Métivier, D; Paulau, AL; Perfettini, JL; Rizzuto, R; Roumier, T; Simoni, AM; Szabadkai, G | 1 |
| Bendfeldt, K; Bode, H; Fromm, M; Kraemer, OH; Kroesen, AJ; Lenzner, L; Schulzke, JD; Stoltenburg-Didinger, G; Ullrich, R; Zeitz, M | 1 |
| Andersen, AB; Black, FT; Gerstoft, J; Hansen, IM; Justesen, US; Klitgaard, NA; Mathiesen, LR; Pedersen, C | 1 |
| Brun, S; Cernohous, P; Da Silva, B; Omachi, JH; Rouster, SD; Sherman, KE; Shire, NJ | 1 |
| Aldámiz-Echevarría, L; Elorz, J; Pocheville, I; Prieto, JA; Rodríguez-Soriano, J; Sanjurjo, P | 1 |
| Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R | 1 |
| Bonnet, B; Diquet, B; Duval, X; Goujard, C; Katlama, C; Legrand, M; Leport, C; Mentré, F; Panhard, X; Peytavin, G; Salmon-Céron, D; Taburet, AM; Vincent, I | 1 |
| Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS | 1 |
| Crane, HM; Kitahata, MM; Van Rompaey, SE | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Bates, DE; Herman, RJ | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Garazzino, S; Tettoni, M | 1 |
| Aymard, G; Bergmann, JF; Mahé, I; Mouly, S; Rizzo-Padoin, N; Salvat, C; Simoneau, G; Verstuyft, C | 1 |
| Harris, M; Hogg, RS; Montaner, JS; Moore, DM; Wood, E; Yip, B | 1 |
| Alviano, CS; dos Santos, AL; Kneipp, LF; Palmeira, VF | 1 |
| Abecasis, AB; Bacheler, LT; Camacho, RJ; Carvalho, AP; Deforche, K; Gomes, P; McKenna, P; Vandamme, AM | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Alvanzo, A; Baker, J; Friedland, G; Jatlow, P; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, P; Rainey, PM; Smith, PF | 1 |
| Atzori, C; Cargnel, A; Maruzzi, M; Mazza, F; Regazzi, M; Tronconi, E; Valerio, A; Villani, P | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Doran, PP; Malizia, AP; Powderly, WG; Vioreanu, MH | 1 |
| Arastéh, K; Becker, M; Berger, M; Breske, A; Herzmann, C; Hill, A; Kruse, G; Kurowski, M; Schulbin, H; Steinmüller, J; Stocker, H | 1 |
| Chew, N; Cotter, E; Doran, PP; Malizia, AP; Powderly, WG | 1 |
| Focosi, D; Foley, KF; Kast, RE | 1 |
| Badley, AD; Bennett, SA; Vlahakis, SR; Whitehead, SN | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Desai, P; Dixit, V; Hariparsad, N; Li, F; Thummel, KE; Unadkat, JD | 1 |
| Chrysos, G; Kokkoris, S; Kontochristopoulos, G; Mikros, S; Pastelli, A | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Alonso-Socas, Mdel M; Delgado, R; García-Bujalance, S; Garriga, C; Menéndez-Arias, L; Nájera, R; Pérez-Elías, MJ; Pumarola, T; Ruiz, L | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Chao, Y; Grigorian, A; Hurford, R; Langford, TD; Patrick, C | 1 |
| Burri, M; Nadal, D; Rode, R; Rudin, C; Shen, Y | 1 |
| Houston, JB; Parker, AJ | 1 |
| Fulco, PP; Higginson, RT; Zingone, MM | 1 |
| Garg, R; Messier, N; Ouellette, M; Sundar, S; Tremblay, MJ; Trudel, N | 1 |
| Krauchenco, S; Martins, NH; Polikarpov, I; Sanches, M | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Chow, WA; Guan, M; Jiang, C | 1 |
| Algeciras-Schimnich, A; Badley, AD; Bren, GD; Chari, ST; Dawra, RK; Navina, S; Rizza, SA; Saluja, AK; Schnepple, D; Singh, VP; Vege, SS | 1 |
| Bukrinsky, M; Cui, HL; Dart, A; Grant, A; Mukhamedova, N; Rose, H; Sviridov, D; Tchoua, U | 1 |
| Chen, L; Chen, X; He, Z; Qin, L; You, J | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Annaert, P; Augustijns, P; Camus, S; Ye, ZW | 1 |
| Baki, L; Baumgarten, CM; Deng, W; Yin, J; Zhou, H | 1 |
| Adnot, S; Amsellem, V; Brégeon, J; Dubois-Randé, JL; Gary-Bobo, G; Houssaini, A; Marcos, E; Pacaud, P; Perrin, A; Rideau, D; Savale, L; Sitbon, O | 1 |
| Antoine, B; Capeau, J; Chapron, C; Kadiri, S; Leroyer, S; Quette, J; Vatier, C | 1 |
| Collier, AC; Kharasch, ED; Kirby, BJ; Thummel, KE; Unadkat, JD; Whittington, D | 2 |
| Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Collier, AC; Desai, P; Dixit, V; Kharasch, ED; Kirby, BJ; Thummel, KE; Unadkat, JD; Whittington, D | 1 |
| Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ | 1 |
| Fätkenheuer, G; Hartmann, P; Jung, N; Lehmann, C; Rubbert, A; Schömig, E; Taubert, D | 1 |
| Liu, L; Unadkat, JD | 1 |
| Arend, C; Brandmann, M; Dringen, R | 1 |
| Ambudkar, SV; Cheepala, SB; Ekins, S; Fukuda, Y; Schuetz, JD; Sparreboom, A; Takenaka, K; Wu, CP | 1 |
| Bader, J; Driessen, C; Kraus, M; Müller-Ide, H; Overkleeft, H; Rückrich, T | 1 |
| Brandmann, M; Dringen, R; Hohnholt, MC; Petters, C | 1 |
| Anderson, AM; Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Gottlieb, GS; Tchounga, BK; Tegbe, J; Vitoria, M | 1 |
| Haugaard, SB | 1 |
| Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A | 1 |
| Asano, T; Isono, M; Okubo, K; Sato, A | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Amadori, L; Björkegren, JLM; Crane, HM; Crane, PK; Dudley, JT; Frades, I; Giannarelli, C; Koplev, S; Kovacic, JC; Peter, I; Readhead, B; Talukdar, HA | 1 |
| Kim, JY; Lee, BM; Park, YJ; Yoon, S | 1 |
| Wang, RG; Zhang, HX; Zheng, QC | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
| Bissaro, M; Bolcato, G; Moro, S; Pavan, M; Sturlese, M | 1 |
| Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X | 1 |
| Abdelnabi, R; Annaert, PP; Augustijns, PF; Cambier, S; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Delang, L; Foo, CS; Gouwy, M; Heylen, E; Jochmans, D; Kaptein, SJF; Leyssen, P; Mols, R; Neyts, J; Proost, P; Rocha-Pereira, J; Ter Horst, S; van Laer, C; Vandooren, J; Vangeel, L; Vergote, V; Weynand, B; Zhang, X | 1 |
| Baniwal, P; Inbaraj, BS; Kashyap, P; Kumar, S; Sharma, M; Shikha, D; Singh, N; Sridhar, K; Thakur, M; Yadav, YS | 1 |
34 review(s) available for nelfinavir and ritonavir
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
HIV-1 protease inhibitors. A review for clinicians.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1997 |
Human immunodeficiency virus type 1 protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Interactions; Drug Resistance; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Sulfonic Acids | 1997 |
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Drug Approval; Drug Costs; Drug Interactions; Health Policy; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Life Style; Nelfinavir; Primary Prevention; Ritonavir; Saquinavir; United States; United States Food and Drug Administration; Viral Load | 1997 |
[Clinical application of HIV protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Resistance to human immunodeficiency virus type 1 protease inhibitors.
Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides | 1998 |
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retina; Retinal Diseases; Ritonavir; Saquinavir | 1998 |
Development of HIV protease inhibitors: a survey.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship | 1998 |
Simultaneous use of two protease inhibitors in HIV infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Drug interactions of HIV protease inhibitors.
Topics: Anti-Infective Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Topics: Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Lipodystrophy; Nelfinavir; Ritonavir; Saquinavir | 1999 |
[HIV protease inhibitors: drug interactions].
Topics: Anti-HIV Agents; Contraindications; Drug Interactions; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Risk Factors; Ritonavir; Saquinavir | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
HIV protease as a target for retrovirus vector-mediated gene therapy.
Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection | 2000 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides | 2000 |
The choice of HIV protease inhibitor: indinavir is currently the best option.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Treatment Outcome | 1999 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
Pharmacology and clinical experience with saquinavir.
Topics: Biological Availability; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Virus Replication | 2001 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir.
Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Doxorubicin; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2007 |
HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo.
Topics: Animals; Apoptosis; Hippocampus; HIV Infections; HIV Protease Inhibitors; Humans; Mitochondrial ADP, ATP Translocases; Nelfinavir; Pancreatitis; Ritonavir; Signal Transduction; Stroke; T-Lymphocytes | 2007 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Anti-HIV drugs for cancer therapeutics: back to the future?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Neoplasms; Organophosphonates; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2009 |
Antiretroviral therapy response among HIV-2 infected patients: a systematic review.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Female; HIV Infections; HIV-2; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Ritonavir; Treatment Outcome | 2014 |
Alteration in pancreatic islet function in human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Nelfinavir; Ritonavir; Sulfonamides | 2014 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Diosmin; Flavonoids; Hesperidin; Humans; Lopinavir; Molecular Docking Simulation; Nelfinavir; Ritonavir; Rutin; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
44 trial(s) available for nelfinavir and ritonavir
| Article | Year |
|---|---|
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance.
Topics: Drug Resistance, Microbial; Genes, env; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Ritonavir; Viremia | 1998 |
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Predictive Value of Tests; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Treatment Failure; Viral Load | 1999 |
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2000 |
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarnet; Ganciclovir; HIV Protease Inhibitors; Humans; Incidence; Indinavir; Nelfinavir; Outcome Assessment, Health Care; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Treatment Outcome | 2000 |
Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cell Differentiation; Child; Coculture Techniques; Female; HIV Infections; HIV-1; Humans; Immunophenotyping; Infant; Lamivudine; Leukocytes, Mononuclear; Male; Nelfinavir; Prospective Studies; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Virus Replication; Zidovudine | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Infant; Male; Nelfinavir; Nevirapine; Puerto Rico; Racial Groups; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; United States; Viral Load | 2000 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir | 2000 |
Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; RNA, Viral | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Prospective Studies; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Mutation; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2001 |
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; Erectile Dysfunction; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Multivariate Analysis; Nelfinavir; Prevalence; Risk Factors; Ritonavir; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2001 |
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Time; Viral Load; Zidovudine | 2001 |
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Triglycerides | 2001 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Administration Schedule; Humans; Lamivudine; Nelfinavir; Nevirapine; Patient Compliance; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2002 |
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load | 2002 |
Low-dose ritonavir moderately enhances nelfinavir exposure.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Ritonavir; Time Factors | 2002 |
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.
Topics: Administration, Oral; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Models, Biological; Models, Chemical; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Diurnal variation of plasma protease inhibitor concentrations.
Topics: Circadian Rhythm; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Eating; Female; Half-Life; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Ritonavir | 2003 |
Sildenafil does not alter nelfinavir pharmacokinetics.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Erectile Dysfunction; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Piperazines; Purines; Ritonavir; Saquinavir; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2003 |
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Female; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load | 2004 |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir | 2003 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors | 2004 |
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load | 2004 |
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides | 2004 |
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir | 2004 |
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
Topics: Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Odds Ratio; Patient Compliance; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Viral Load | 2005 |
The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Male; Middle Aged; Nelfinavir; Prospective Studies; Ritonavir; Viral Load | 2005 |
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2005 |
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Outcome | 2005 |
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Multicenter Studies as Topic; Nelfinavir; Patient Compliance; Prospective Studies; Ritonavir; Viral Load | 2005 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Topics: Administration, Oral; Adolescent; Adult; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Activation; Enzyme Induction; Female; HIV Protease Inhibitors; Humans; Injections, Intravenous; Intestines; Liver; Male; Midazolam; Middle Aged; Nelfinavir; Rifampin; Ritonavir; Substrate Specificity; Tissue Distribution; Young Adult | 2011 |
234 other study(ies) available for nelfinavir and ritonavir
| Article | Year |
|---|---|
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Topics: Anti-HIV Agents; Drug Design; HIV Protease Inhibitors; Thiazoles | 2000 |
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Topics: Animals; Antiviral Agents; Cattle; Cell Culture Techniques; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Haplorhini; HIV Protease Inhibitors; HIV-1; Humans; Indans; Male; Piperazines; Protein Binding; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Urinary Calculi | 2000 |
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.
Topics: Amides; Cell Line; Cloning, Molecular; Crystallography, X-Ray; Drug Design; Escherichia coli; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indans; Models, Molecular; Mutation; Structure-Activity Relationship | 2001 |
Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
Topics: Cell Line; Cloning, Molecular; Cytopathogenic Effect, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Thiophenes | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
Topics: Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; Kinetics; Protein Binding; Structure-Activity Relationship; Surface Plasmon Resonance; Urea | 2002 |
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antitubercular; Carrier Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Estradiol; Genes, Reporter; Hepatocytes; Humans; In Vitro Techniques; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Organic Anion Transporters, Sodium-Dependent; Organic Cation Transporter 1; Plasmids; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rifampin; Symporters; Transcriptional Activation; Transfection | 2003 |
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Topics: Binding Sites; Binding, Competitive; Catalysis; Drug Resistance, Viral; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Chemical; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship; Thermodynamics | 2003 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine | 2003 |
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression; HIV Protease Inhibitors; Humans; Indinavir; Mitoxantrone; Nelfinavir; Neoplasm Proteins; Ritonavir; Saquinavir; Tritium | 2004 |
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Topics: Binding Sites; Crystallography, X-Ray; Dimerization; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Indinavir; Kinetics; Models, Molecular; Molecular Structure; Mutation; Protein Structure, Tertiary; Thermodynamics | 2004 |
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication | 2004 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids | 2005 |
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Topics: Drug Design; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Conformation; Pyrimidinones; Quantitative Structure-Activity Relationship | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
Topics: Amides; Cell Line; Cysteine; HIV; HIV Protease Inhibitors; Humans; Models, Molecular; Phenylbutyrates; Thiazoles | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship | 2008 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Topics: Amino Acids; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Models, Molecular; Mutation; Phenylbutyrates; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2008 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Topics: Aspartic Acid Endopeptidases; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Protease Inhibitors; Indinavir; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids | 1996 |
More new drugs for HIV and associated infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Isoquinolines; Nelfinavir; Nevirapine; Organophosphonates; Organophosphorus Compounds; Protease Inhibitors; Pyridines; Ritonavir; Sulfonic Acids | 1997 |
FDA rapidly approves HIV protease inhibitors for children.
Topics: Adult; Anti-HIV Agents; Child; Drug Industry; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
FDA approvals include two new AIDS drugs, pediatric labeling for two protease inhibitors.
Topics: Adolescent; Adult; Child; Child, Preschool; Delavirdine; Drug Approval; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Isoquinolines; Nelfinavir; Piperazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Hundreds enrolled in canadian HIV trials.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Canada; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Prednisone; Randomized Controlled Trials as Topic; Ritonavir; Sulfonic Acids; Vincristine; Zidovudine | 1997 |
Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA Primers; Drug Therapy, Combination; HIV-1; Humans; Indinavir; Isoquinolines; Leukocytes, Mononuclear; Nelfinavir; Polymerase Chain Reaction; Ritonavir; RNA Splicing; RNA, Messenger; RNA, Viral; Sulfonic Acids; Virus Replication; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Education as Topic; Primary Nursing; Ritonavir; Saquinavir | 1998 |
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Topics: Diabetes Complications; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1997 |
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Topics: Adult; Anti-HIV Agents; Body Composition; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Insulin Resistance; Lipodystrophy; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Syndrome | 1998 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Topics: Anti-HIV Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Indinavir; Leukemia, Erythroblastic, Acute; Nelfinavir; Paclitaxel; Ritonavir; Saquinavir; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Vinblastine | 1998 |
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 1999 |
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure; Viral Load | 1999 |
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir | 1999 |
A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
Topics: Anti-HIV Agents; CD4 Antigens; Drug Evaluation, Preclinical; Gene Expression; Gene Products, rev; Gene Products, tat; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Interferon-alpha; Nelfinavir; rev Gene Products, Human Immunodeficiency Virus; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zidovudine | 1999 |
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Arteriosclerosis; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indinavir; Lipids; Lipoprotein(a); Lipoproteins; Logistic Models; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Thyrotropin | 1999 |
Effect of protease inhibitors on the sense of taste.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Taste; Taste Disorders | 1999 |
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Flow Cytometry; Fluorescent Dyes; HIV Protease Inhibitors; Humans; Indinavir; Lymphocytes; Nelfinavir; Rhodamine 123; Ritonavir; Saquinavir; Temperature; Verapamil | 1999 |
Inhibition of adipocyte differentiation by HIV protease inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Carbamates; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Furans; Gene Expression; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Mice; Myelin P2 Protein; Nelfinavir; Neoplasm Proteins; Nerve Tissue Proteins; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Ritonavir; Stem Cells; Sulfonamides; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 1999 |
Two possible pathways for acquisition of mutations related to nelfinavir resistance.
Topics: Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Pharmacokinetic interactions between HIV-protease inhibitors in rats.
Topics: Acquired Immunodeficiency Syndrome; Animals; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Male; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir | 1999 |
Influence of protease inhibitor therapy on lipoprotein metabolism.
Topics: Adult; CD4 Lymphocyte Count; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Lipoproteins; Male; Middle Aged; Nelfinavir; Prospective Studies; Ritonavir; Viral Load | 1999 |
Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir | 2000 |
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Venous Thrombosis | 1999 |
The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Topics: HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Mucosa; Ion Transport; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir; Salvage Therapy; Saquinavir; Treatment Outcome | 2000 |
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carbon Radioisotopes; Carrier Proteins; Dose-Response Relationship, Drug; Gene Expression; HeLa Cells; HIV Protease Inhibitors; Humans; Indinavir; Membrane Proteins; Multidrug Resistance-Associated Proteins; Nelfinavir; Organic Cation Transporter 1; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Saquinavir; Tetraethylammonium; Tumor Cells, Cultured | 2000 |
Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.
Topics: Drug Design; Enzymes, Immobilized; HIV Protease; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Kinetics; Molecular Weight; Nelfinavir; Ritonavir; Saquinavir; Surface Plasmon Resonance | 2000 |
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Topics: Antidepressive Agents, Second-Generation; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Microsomes, Liver; Nelfinavir; Oxidoreductases, N-Demethylating; Piperazines; Ritonavir; Saquinavir; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Trazodone | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Jurkat Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Cohort Studies; Confidence Intervals; Drug Monitoring; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Incidence; Indinavir; Italy; Male; Middle Aged; Multivariate Analysis; Nelfinavir; Prospective Studies; Risk Factors; Ritonavir; Saquinavir | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Hyperlipidemia associated with the use of protease inhibitors.
Topics: Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Triglycerides | 2000 |
Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
Topics: Carbamates; Chromatography, Liquid; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
Topics: Animals; Anti-HIV Agents; Antiprotozoal Agents; Coccidiostats; Drug Evaluation, Preclinical; Drug Interactions; Nelfinavir; Pyrimethamine; Ritonavir; Sulfadiazine; Toxoplasma | 2000 |
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
Topics: Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutagenesis, Site-Directed; Mutation; Nelfinavir; Polymerase Chain Reaction; Ritonavir; Saquinavir; Virus Replication | 2000 |
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Topics: Amino Acid Substitution; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Drug Resistance, Microbial; Entropy; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Mutagenesis, Site-Directed; Nelfinavir; Phenylalanine; Protons; Ritonavir; Saquinavir; Thermodynamics; Valine | 2000 |
Switching antiretroviral therapy from an enzyme-inducing drug.
Topics: Adult; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Viral Load | 2000 |
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Topics: Adult; Chromatography, High Pressure Liquid; Cohort Studies; DNA, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Sequence Analysis, DNA; Viral Load | 2000 |
HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Topics: Acyltransferases; Animals; Blood Glucose; Carbon Radioisotopes; Cholesterol; Diacylglycerol O-Acyltransferase; Fasting; Fatty Acid Synthases; Fatty Acids; HIV Protease Inhibitors; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Nicotinic Acids; Postprandial Period; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Saquinavir; Tetrahydronaphthalenes; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2000 |
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Drug Interactions; Fluoresceins; Fluorescent Dyes; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kinetics; LLC-PK1 Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Swine; Transfection | 2000 |
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea | 2000 |
[Resistance to protease inhibitors: the role of the MDR gene].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Proteins; Biological Availability; Calcium Channel Blockers; Carrier Proteins; Drug Resistance, Microbial; Gene Expression Regulation; Humans; K562 Cells; Membrane Transport Proteins; Nelfinavir; Protease Inhibitors; Ritonavir; Verapamil | 2000 |
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Topics: Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Bupropion; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; Hydroxylation; Inhibitory Concentration 50; Microsomes, Liver; Nelfinavir; Oxazines; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors; Ritonavir | 2001 |
Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
Topics: Acquired Immunodeficiency Syndrome; Colon; Diarrhea; HIV Protease Inhibitors; HT29 Cells; Humans; Indinavir; Intestinal Absorption; Intestinal Mucosa; Nelfinavir; Ritonavir; Saquinavir | 2000 |
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indicators and Reagents; Indinavir; Nelfinavir; Reference Standards; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 2001 |
The safety and antiviral effect of protease inhibitors in children.
Topics: Adolescent; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2001 |
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Topics: Adult; Amino Acid Sequence; Catalysis; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Protein Structure, Secondary; Ritonavir; Saquinavir; Uganda | 2001 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1998 |
Viracept combination studies.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine | 1998 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
Anti-HIV agents at ICAAC.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Kidney; Mutation; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonic Acids; Treatment Failure; Viral Load | 1996 |
Pediatric treatments.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonic Acids | 1997 |
Update on antivirals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1997 |
Combinations of protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1998 |
Pregnant pause.
Topics: Anti-HIV Agents; Contraceptives, Oral; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir | 1998 |
Antivirals and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Nelfinavir; Practice Guidelines as Topic; Ritonavir; Saquinavir; Viral Load | 1998 |
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Saquinavir | 2001 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
Topics: Amino Acid Substitution; Biosensing Techniques; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Kinetics; Mathematics; Mutation; Nelfinavir; Protein Binding; Ritonavir; Saquinavir; Thermodynamics | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Follow-Up Studies; HIV Infections; Humans; Indinavir; Longitudinal Studies; Middle Aged; Nelfinavir; Prevalence; Protease Inhibitors; Ritonavir; Saquinavir; Viral Load | 2001 |
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Topics: Adipose Tissue; Adult; Aged; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; Saquinavir; Triglycerides | 2001 |
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Topics: Adult; Antigens, CD34; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fluorescent Dyes; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Lymphocytes; Male; Nelfinavir; Rhodamine 123; Ritonavir; RNA, Viral; Saquinavir | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
Topics: Apoptosis; Caspases; HIV Protease Inhibitors; Humans; Intracellular Membranes; Jurkat Cells; Membrane Potentials; Mitochondria; Nelfinavir; Ritonavir; Saquinavir; Tumor Cells, Cultured; Zidovudine | 2001 |
P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; CD4-Positive T-Lymphocytes; Cell Line; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Multidrug Resistance-Associated Proteins; Nelfinavir; Ritonavir; Saquinavir | 2001 |
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Odds Ratio; Patient Compliance; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Surveys and Questionnaires | 2001 |
Kaletra versus nelfinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Viral Load | 2001 |
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Female; Gene Expression; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides | 2002 |
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Topics: Acquired Immunodeficiency Syndrome; Binding Sites; Biological Evolution; Computational Biology; Computer Simulation; Computer-Aided Design; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Molecular; Mutation; Nelfinavir; Ritonavir; Saquinavir | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Male sexual dysfunction associated with antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Cohort Studies; Erectile Dysfunction; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Managed Care Programs; Middle Aged; Nelfinavir; New England; Retrospective Studies; Ritonavir; Saquinavir | 2002 |
Increasing choices for HIV therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2002 |
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Topics: Africa; Amides; Amino Acid Substitution; Anti-HIV Agents; Calorimetry; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Kinetics; Mutagenesis, Site-Directed; Nelfinavir; Phenotype; Polymorphism, Genetic; Recombinant Proteins; Ritonavir; Saquinavir; Thermodynamics; Thiazoles | 2002 |
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.
Topics: Chromatography, High Pressure Liquid; HIV Protease Inhibitors; Humans; Nelfinavir; Reference Standards; Ritonavir; Saquinavir; Sensitivity and Specificity | 2002 |
Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.
Topics: Alkynes; Anti-HIV Agents; Antihypertensive Agents; Benzoxazines; Cyclopropanes; Delayed-Action Preparations; Drug Interactions; HIV Protease Inhibitors; Humans; Hypotension, Orthostatic; Male; Middle Aged; Nelfinavir; Nifedipine; Oxazines; Ritonavir | 2002 |
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Composition; HIV Protease Inhibitors; Homeostasis; Humans; Indinavir; Insulin; Leptin; Lipids; Lipodystrophy; Magnetic Resonance Imaging; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Drug Interactions; fas Receptor; HIV Protease Inhibitors; Humans; Indinavir; Jurkat Cells; Nelfinavir; Ritonavir; Saquinavir; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Bone Remodeling; Calcitriol; Cell Line; Cholestanetriol 26-Monooxygenase; Cytochrome P-450 Enzyme System; Depression, Chemical; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Macrophages; Nelfinavir; Ritonavir; Steroid Hydroxylases; Vitamin D; Vitamin D3 24-Hydroxylase | 2003 |
Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Benzoxazines; Bupropion; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Retrospective Studies; Ritonavir; Seizures | 2003 |
SOLO trial results released.
Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; Humans; Nelfinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2003 |
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Topics: Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Drug Interactions; HIV; HIV Infections; Humans; Infant; Male; Mycobacterium tuberculosis; Nelfinavir; Rifampin; Ritonavir; RNA, Viral; Tuberculosis, Pulmonary; Viral Load | 2003 |
Resistance data also presented.
Topics: Drug Resistance, Viral; HIV Infections; Humans; Nelfinavir; Ritonavir; Treatment Outcome | 2003 |
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2003 |
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir | 2003 |
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Topics: Animals; Carbamates; Cells, Cultured; Furans; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nelfinavir; Ritonavir; Sulfonamides | 2003 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Carrier Proteins; CD3 Complex; Cell Line; Cells, Cultured; Cysteine Endopeptidases; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; HIV Envelope Protein gp120; HIV Protease Inhibitors; Humans; Immunoblotting; Indinavir; Interferon-gamma; Membrane Glycoproteins; Mice; Multienzyme Complexes; Nelfinavir; Osteoclasts; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Binding; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Ritonavir | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.
Topics: Adult; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir | 2003 |
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine | 2003 |
[A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].
Topics: Acquired Immunodeficiency Syndrome; Drug Synergism; Drug Therapy, Combination; Food-Drug Interactions; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Nelfinavir; Randomized Controlled Trials as Topic; Ritonavir | 2003 |
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Fluorescent Antibody Technique; HIV Protease Inhibitors; Lethal Dose 50; Nelfinavir; Ritonavir; RNA, Viral; Severe acute respiratory syndrome-related coronavirus; Time Factors; Vero Cells; Virus Replication | 2004 |
Direct interference of HIV protease inhibitors with pancreatic beta-cell function.
Topics: Animals; Calcium; Calcium Channels; Cells, Cultured; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Membrane Potentials; Mice; Nelfinavir; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Radioimmunoassay; Ritonavir | 2004 |
Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
Topics: Adult; Anti-Retroviral Agents; Antidiarrheals; Antiretroviral Therapy, Highly Active; Cohort Studies; Diarrhea; Georgia; HIV Infections; Humans; Incidence; Lopinavir; Middle Aged; Nelfinavir; Pyrimidinones; Retrospective Studies; Ritonavir; United States; United States Department of Veterans Affairs | 2004 |
Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Cecum; Cytokines; Drug Evaluation, Preclinical; Enterococcus; Escherichia coli; Female; Genes, RAG-1; Germ-Free Life; Intestinal Perforation; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Nelfinavir; Protease Inhibitors; Pseudomonas aeruginosa; Ritonavir; Sepsis; Spleen; Streptococcus bovis; Thymus Gland | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Oligopeptides; Organophosphonates; Oxazines; Pregnancy; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Fibrinolytic Agents; HIV Protease Inhibitors; Indinavir; Intercellular Signaling Peptides and Proteins; Interleukin-6; Mice; Nelfinavir; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Zidovudine | 2005 |
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.
Topics: Animals; Antibodies; Apoptosis; Disease Models, Animal; Female; Hepatitis; HIV Protease Inhibitors; Humans; Jurkat Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitochondrial ADP, ATP Translocases; Models, Molecular; Nelfinavir; Ritonavir; Shock, Septic; Signal Transduction; Stroke | 2005 |
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System | 2005 |
HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.
Topics: Apoptosis; Calcium; Ceramides; Cytomegalovirus; Giant Cells; HeLa Cells; HIV Protease Inhibitors; Humans; Hydrogen Peroxide; Immediate-Early Proteins; Inhibitor of Apoptosis Proteins; Macrophage Inflammatory Proteins; Mitochondria; Nelfinavir; Ritonavir; Saquinavir; Tumor Suppressor Protein p53; Viral Proteins | 2006 |
The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.
Topics: Adult; Aged; Apoptosis; Cells, Cultured; Colon; Enzyme-Linked Immunosorbent Assay; Female; HIV Protease Inhibitors; Humans; Intestinal Mucosa; L-Lactate Dehydrogenase; Male; Middle Aged; Nelfinavir; Nucleosomes; Ritonavir; Saquinavir | 2005 |
HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Action Potentials; Animals; Anions; Calcium; Cell Membrane; Clotrimazole; Electrophysiology; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Insulin-Secreting Cells; Ion Channels; Membrane Potentials; Mice; Nelfinavir; Patch-Clamp Techniques; Potassium Channel Blockers; Ritonavir; Tetraethylammonium | 2006 |
Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors.
Topics: Child; Cholesterol; Cross-Sectional Studies; Fatty Acids; Fatty Acids, Unsaturated; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin-Like Growth Factor I; Male; Nelfinavir; Ritonavir; Triglycerides | 2005 |
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone | 2006 |
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
Topics: Anticonvulsants; Antiretroviral Therapy, Highly Active; Blood Cell Count; Carbamazepine; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Seropositivity; Humans; Liver Function Tests; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Sleep Stages; Viral Load | 2006 |
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.
Topics: Adult; Antifungal Agents; Drug Synergism; Drug Therapy, Combination; Fluconazole; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Ritonavir | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; HIV Infections; Humans; Indinavir; Liver; Male; Nelfinavir; Nevirapine; Ritonavir; Sex Factors | 2006 |
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nelfinavir; Patient Compliance; Pyrimidinones; Ritonavir; Saquinavir; Viral Load | 2006 |
Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
Topics: Ascomycota; Culture Media; Enzyme Activation; Fungal Proteins; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Indinavir; Mycelium; Nelfinavir; Pepstatins; Peptide Hydrolases; Ritonavir; Saquinavir; Time Factors | 2006 |
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.
Topics: Algorithms; Bayes Theorem; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Genetic; Nelfinavir; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland | 2006 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
Topics: Adult; Buprenorphine; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Lopinavir; Male; Narcotic Antagonists; Nelfinavir; Opioid-Related Disorders; Probability; Pyrimidinones; Reference Values; Risk Assessment; Ritonavir | 2006 |
Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; Bronchoalveolar Lavage Fluid; Bronchoscopy; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumocystis carinii; Pneumocystis Infections; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts.
Topics: Cells, Cultured; Chemokine CCL2; Chemokines; Gene Expression Profiling; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Interleukin-8; Nelfinavir; Oligonucleotide Array Sequence Analysis; Osteoblasts; Ritonavir | 2007 |
Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2007 |
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
Topics: Alkaline Phosphatase; Calcium; Cell Line; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oligonucleotide Array Sequence Analysis; Osteoblasts; Ritonavir; Saquinavir; Tissue Inhibitor of Metalloproteinase-3; Up-Regulation | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Child, Preschool; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Hepatocytes; HIV Protease Inhibitors; Humans; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Organic Anion Transporters; Rifampin; Ritonavir; RNA, Messenger | 2007 |
Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
Topics: Alopecia; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2007 |
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Topics: Amino Acid Substitution; Databases, Protein; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Mutation; Nelfinavir; Pyrimidinones; Ritonavir; Spain; Treatment Failure | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.
Topics: Aspartic Acid Endopeptidases; Cell Survival; Cells, Cultured; Cerebral Arteries; Cerebral Veins; Endothelial Cells; Frontal Lobe; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins; Reactive Oxygen Species; Receptor, Notch1; Receptor, Notch4; Receptors, Notch; Repressor Proteins; Ritonavir; Saquinavir; Vitamin E | 2008 |
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Longitudinal Studies; Lopinavir; Male; Nelfinavir; Pregnancy; Pyrimidinones; Ritonavir; Switzerland; Treatment Outcome; Viral Load; Withholding Treatment | 2008 |
Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.
Topics: Animals; Chromatography, Liquid; HIV Protease Inhibitors; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Sprague-Dawley; Ritonavir; Saquinavir; Tandem Mass Spectrometry | 2008 |
Possible antiretroviral therapy-warfarin drug interaction.
Topics: Adult; Anticoagulants; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Humans; Lopinavir; Middle Aged; Nelfinavir; Nevirapine; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Warfarin | 2008 |
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.
Topics: Animals; Cell Line, Tumor; HIV Protease Inhibitors; Humans; Leishmania; Leishmaniasis, Visceral; Lethal Dose 50; Macrophages; Nelfinavir; Ritonavir; Saquinavir | 2008 |
Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
Topics: Amino Acid Sequence; Binding Sites; Drug Resistance, Viral; Enzyme Activation; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Microbial Viability; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Ritonavir; Sequence Alignment | 2009 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.
Topics: Amylases; Animals; Apoptosis; Caspase 3; Ceruletide; Cytochromes c; Disease Models, Animal; Drug Therapy, Combination; HIV Protease Inhibitors; Inflammation Mediators; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria; Necrosis; Nelfinavir; Pancreas; Pancreatitis; Ritonavir; Trypsin | 2009 |
Antiretroviral compounds and cholesterol efflux from macrophages.
Topics: Animals; Anti-Retroviral Agents; Apoptosis; Cell Line; Cholesterol; Cholesterol, HDL; HIV Infections; Humans; Macrophages; Mice; Nelfinavir; Ritonavir | 2009 |
Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.
Topics: Animals; Anti-Retroviral Agents; Antimalarials; Chloroquine; Drug Resistance; Drug Synergism; Female; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; HIV Protease Inhibitors; Inhibitory Concentration 50; Malaria; Mice; Nelfinavir; Plasmodium chabaudi; Plasmodium falciparum; Ritonavir; Saquinavir | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
Topics: Action Potentials; Animals; Carbamates; Chloride Channels; Furans; HIV Integrase Inhibitors; HIV Protease Inhibitors; Ion Channel Gating; Lopinavir; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Nelfinavir; Pyrimidinones; Pyrrolidinones; Rabbits; Raltegravir Potassium; Reactive Oxygen Species; Ritonavir; Sulfonamides; Time Factors | 2010 |
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.
Topics: Animals; Animals, Newborn; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Pressure; Carbamates; Cell Division; Furans; Hemodynamics; HIV Protease Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Nelfinavir; Pulmonary Artery; Rats; Rats, Wistar; Ritonavir; Sulfonamides | 2010 |
Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.
Topics: Adult; Atazanavir Sulfate; Carrier Proteins; Female; Gene Expression; HIV Protease Inhibitors; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Lopinavir; Male; Nelfinavir; Oligopeptides; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Pyridines; Pyrimidinones; Ritonavir; Sesquiterpenes; Subcutaneous Fat; Triglycerides; Tumor Necrosis Factor-alpha | 2011 |
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2012 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
Topics: Cytochrome P-450 Enzyme System; Enzyme Induction; HIV Protease Inhibitors; Humans; In Vitro Techniques; Nelfinavir; Ritonavir | 2011 |
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides | 2012 |
Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Bupropion; Digoxin; Drug Administration Schedule; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Rifampin; Ritonavir | 2012 |
Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Cytidine Triphosphate; Dideoxynucleotides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Phosphorylation; Real-Time Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Tandem Mass Spectrometry; Transfection; Young Adult | 2013 |
Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
Topics: Carbamates; Cells, Cultured; Drug Interactions; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Organic Anion Transporters; Ritonavir; Sulfonamides | 2013 |
The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.
Topics: Animals; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cells, Cultured; Drug Combinations; Glutathione; HIV Protease Inhibitors; Indinavir; Nelfinavir; Propionates; Quinolines; Rats; Rats, Wistar; Ritonavir | 2013 |
Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Hydrolysis; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Molecular; Multidrug Resistance-Associated Proteins; Nelfinavir; Organophosphonates; Ritonavir | 2013 |
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Topics: Apoptosis; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Leukemic; HIV Protease Inhibitors; Humans; Leukemia, Myeloid, Acute; Lopinavir; Nelfinavir; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Ritonavir; Saquinavir; Signal Transduction; Tumor Cells, Cultured | 2014 |
Antiretroviral protease inhibitors accelerate glutathione export from viable cultured rat neurons.
Topics: Cells, Cultured; Glutathione; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Neurons; Ritonavir | 2014 |
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi | 2014 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lopinavir; Male; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Ritonavir | 2016 |
Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Histones; Humans; Nelfinavir; Ritonavir; Urinary Bladder Neoplasms | 2018 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Arteries; Atherosclerosis; Cholesterol Esters; Coronary Artery Disease; Databases, Nucleic Acid; DNA-Binding Proteins; Foam Cells; Gene Regulatory Networks; HIV Infections; Humans; Macrophages; Nelfinavir; Ritonavir; Saquinavir; THP-1 Cells | 2019 |
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fluphenazine; Furans; HIV Protease Inhibitors; Humans; Ketones; Lopinavir; Mouth Neoplasms; Nelfinavir; Ritonavir; Vincristine | 2019 |
Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Furans; HIV Protease; Indinavir; Molecular Conformation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Protein Binding; Ritonavir; Sulfonamides | 2020 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Repositioning; Humans; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2020 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis | 2021 |
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
Topics: Animals; COVID-19 Drug Treatment; Cricetinae; HIV Infections; HIV Protease Inhibitors; Lopinavir; Lung; Mesocricetus; Nelfinavir; Ritonavir; RNA, Viral; SARS-CoV-2 | 2022 |